Last reviewed · How we verify
Placebo Infusion
Placebo infusion produces therapeutic effects through patient expectation and the placebo effect rather than active pharmacological mechanisms.
At a glance
| Generic name | Placebo Infusion |
|---|---|
| Also known as | ADSC Infusion Therapy Placebo, Sodium chloride (NaCl), lactated ringers, Placebo, Control |
| Sponsor | American CryoStem Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
A placebo infusion is an inert substance administered intravenously that lacks active pharmaceutical ingredients. Its therapeutic effects, when observed, arise from psychological mechanisms including expectation, conditioning, and the patient-provider interaction rather than direct molecular action. This is typically used in clinical research as a control comparator to distinguish true drug effects from placebo responses.
Approved indications
Common side effects
Key clinical trials
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (PHASE2)
- Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (PHASE3)
- MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (PHASE3)
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (PHASE3)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |